ChemoCentryx Inc (ChemoCentryx) is a bio pharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases and inflammatory disorders. The company's lead drug candidate include Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; CCX872, an orally administered inhibitor for pancreatic cancer; and CCX140, an orally-administered inhibitor of the chemokine receptor known for patients with diabetic nephropathy, among others. It also carries out preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.

Headquarters United States of America

Address 835 Industrial Road, Suite 600, San Carlos, California, 94070


Telephone 1 650 2102900

No of Employees 178

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange CCXI (NASD)

Revenue (2020) $32.2M -50.3% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX -138% (2020 vs 2019)

Market Cap* $3.6B

Net Profit Margin (2020) XXX -379.3% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for ChemoCentryx Inc

40+

Clinical Trials

Determine ChemoCentryx Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for ChemoCentryx Inc’s relevant decision makers and contact details.

30+

Pipeline Drugs

Identify which of ChemoCentryx Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

18+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand ChemoCentryx Inc’s commercialized product portfolio to stay one step ahead of the market.

40+

Install Base

Install Base provides the user with a holistic as well as granular level view of the product deployments of leading vendors across geographies and sectors. Using the tool users can also get an understanding of various vendors’ products or solutions deployed by a prospect.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline
CCX168 : for the treatment of Orphan and Rare Diseases
CCX140 : for the treatment of Diabetic Nephropathy
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In August, the company agreed to be acquired by Amgen Inc for US$3.7 billion.
2022 Regulatory Approval In January, the company approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA).
2017 Regulatory Approval In March, the company received the US FDA's Orphan Drug Designation for its avacopan, to treat C3 glomerulopathy (C3G) patients.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters ChemoCentryx Inc Assertio Therapeutics Inc Enzo Biochem Inc MediciNova Inc Galectin Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Carlos Lake Forest Farmingdale La Jolla Norcross
State/Province California Illinois New York California Georgia
No. of Employees 178 - 451 11 9
Entity Type Public Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Thomas J. Schall, Ph.D. Chairman; Chief Executive Officer; President Executive Board 2012 61
Rita Jain, M.D. Chief Medical Officer; Director; Senior Vice President Executive Board 2019 58
Susan M. Kanaya Chief Financial Officer; Chief Administrative Officer; Secretary; Executive Vice President Senior Management 2021 58
Tausif Butt Chief Operating Officer; Executive Vice President Senior Management 2021 -
Catherine L. Kelleher Senior Vice President - Clinical Development Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer